Biosimilars

The Pharmacy Times® Biosimilars Resource Center is a comprehensive resource for clinical news and expert insights on issues related to biosimilar drugs, a biological product that is highly similar to a reference biologic for which there are no clinically meaningful differences in terms of safety, purity, and efficacy.

Latest News

Adalimumab injections -- Image credit: luchschenF | stock.adobe.com
FDA Approves High-Concentration, Citrate-Free Cyltezo for the Treatment of Chronic Inflammatory Diseases

May 2nd 2024

This citrate-free and high-dose approval of the biosimilar Humira provides another option to treat patients who are living with various inflammatory diseases.

Navigating Biosimilar Lifecycles: Key Considerations for Sustainable Cost Savings
Navigating Biosimilar Lifecycles: Key Considerations for Sustainable Cost Savings

May 2nd 2024

3d rendered illustration of lung cancer 3D illustration | Image Credit: appledesign - stock.adobe.com
Samsung Bioepis Initiates Phase 3 Clinical Trial for Proposed Pembrolizumab Biosimilar

April 22nd 2024

Acute psoriasis on the knees, body, elbows | Image Credit: SNAB - stock.adobe.com
FDA Approves Ustekinumab Biosimilar to Stelara for Treatment of Plaque Psoriasis

April 17th 2024

Medically accurate illustration of a womans large intestine | Image Credit: Sebastian Kaulitzki - stock.adobe.com
Study Finds No Differences Between Adalimumab, Biosimilar for Inflammatory Bowel Disease

April 15th 2024

Video Interviews
Podcasts

More News

© 2024 MJH Life Sciences

All rights reserved.